L&C Bio Co. Ltd Market Cap ($399.58 Million)
Market Cap & Net Worth: L&C Bio Co. Ltd (290650)
L&C Bio Co. Ltd market cap. L&C Bio Co. Ltd (KQ:290650) has a market capitalization of $399.58 Million (₩589.62 Billion) as of November 3, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #13060 globally and #377 in its home market, demonstrating a -59.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying L&C Bio Co. Ltd's stock price ₩23950.00 by its total outstanding shares 24618850 (24.62 Million). Also see 290650 operating cash flow for how efficiently the company converts equity into cash flow.
L&C Bio Co. Ltd Market Cap History (2018–2026)
L&C Bio Co. Ltd market cap history from 2018 to 2026. Data shows growth from $107.91 Million to $399.58 Million (13.22% CAGR). Check L&C Bio Co. Ltd stock quote for real-time trading data and today's change.
Index Memberships
L&C Bio Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$208.91 Billion | 0.19% | #103 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$208.91 Billion | 0.19% | #103 of 1384 |
Weight: L&C Bio Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
L&C Bio Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how L&C Bio Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 290650 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.01x
L&C Bio Co. Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
L&C Bio Co. Ltd's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $107.91 Million | $21.24 Billion | $5.21 Billion | 0.01x | 0.02x |
| 2019 | $141.16 Million | $29.15 Billion | $7.25 Billion | 0.00x | 0.02x |
| 2020 | $571.59 Million | $32.97 Billion | $10.81 Billion | 0.02x | 0.05x |
| 2021 | $607.24 Million | $45.68 Billion | $13.81 Billion | 0.01x | 0.04x |
| 2022 | $384.07 Million | $52.57 Billion | $4.54 Billion | 0.01x | 0.08x |
| 2023 | $483.83 Million | $65.93 Billion | $48.36 Billion | 0.01x | 0.01x |
| 2024 | $402.08 Million | $72.09 Billion | $141.06 Billion | 0.01x | 0.00x |
Competitor Companies of 290650 by Market Capitalization
Companies near L&C Bio Co. Ltd in the global market cap rankings as of November 3, 2026. Also see L&C Bio Co. Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to L&C Bio Co. Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $184.67 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #215 globally with a market cap of $111.95 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #225 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $184.67 Billion | $106.20 |
| #215 | Stryker Corporation | NYSE:SYK | $111.95 Billion | $291.86 |
| #225 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $96.54 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of L&C Bio Co. Ltd (2018–2026)
Market capitalization of L&C Bio Co. Ltd from 2018 to today. Between 2018 and today, L&C Bio Co. Ltd's market cap moved from $107.91 Million to $ 399.58 Million, with a yearly change of 13.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩399.58 Million | -60.80% |
| 2025 | ₩1.02 Billion | +153.53% |
| 2024 | ₩402.08 Million | -16.90% |
| 2023 | ₩483.83 Million | +25.97% |
| 2022 | ₩384.07 Million | -36.75% |
| 2021 | ₩607.24 Million | +6.24% |
| 2020 | ₩571.59 Million | +304.91% |
| 2019 | ₩141.16 Million | +30.81% |
| 2018 | ₩107.91 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of L&C Bio Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $399.58 Million USD |
| MoneyControl | $399.58 Million USD |
| MarketWatch | $399.58 Million USD |
| marketcap.company | $399.58 Million USD |
| Reuters | $399.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About L&C Bio Co. Ltd
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. The company offers pharmaceuticals, human tissue, medical device, and cosmetics products. L&C Bio Co., Ltd was founded in 2011 and is headquartered in Seongnam-si, South Korea.